

## Datasheet: MCA216F

**BATCH NUMBER 157694**

<b>Description:</b>	MOUSE ANTI HUMAN CD66b:FITC
<b>Specificity:</b>	CD66b
<b>Other names:</b>	BILIARY GLYCOPROTEIN, CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 8
<b>Format:</b>	FITC
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	80H3
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	100 TESTS/2ml

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat - 1/2

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Human						
<b>Product Form</b>	Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid						
<b>Max Ex/Em</b>	<table border="1"> <thead> <tr> <th>Fluorophore</th> <th>Excitation Max (nm)</th> <th>Emission Max (nm)</th> </tr> </thead> <tbody> <tr> <td>FITC</td> <td>490</td> <td>525</td> </tr> </tbody> </table>	Fluorophore	Excitation Max (nm)	Emission Max (nm)	FITC	490	525
Fluorophore	Excitation Max (nm)	Emission Max (nm)					
FITC	490	525					
<b>Preparation</b>	Purified IgG prepared by affinity chromatography from tissue culture supernatant						
<b>Buffer Solution</b>	Phosphate buffered saline						
<b>Preservative</b>	0.1% Sodium Azide (NaN <sub>3</sub> )						
<b>Stabilisers</b>	0.2% Bovine Serum Albumin						
<b>Immunogen</b>	Human leucocytes from individuals with CML.						

**External Database****Links****UniProt:**[P31997](#)[Related reagents](#)**Entrez Gene:**[1088](#)

CEACAM8

[Related reagents](#)**Synonyms**

CGM6

**RRID**

AB\_2077860

**Fusion Partners**

Spleen cells from immunised BALB/c mice were fused with cells of the mouse MOPC 315-43 myeloma cell line.

**Specificity**

**Mouse anti Human CD66b antibody, clone 80H3** reacts with the CEACAM8 or CGM6 gene product, from the carcinoembryonic gene family. The CEACAM8 gene product is called CD66b, Non-specific cross-reacting antigen NCA-95 or Carcinoembryonic antigen CGM6. CD66b is a 286 amino acid mature ~95-100 kDa GPI anchored molecule with an N-terminal 34 amino acid signal peptide and a 29 amino acid C-terminal propeptide, shed in the mature form. CD66b is expressed strongly by mature granulocytes and metamyelocytes, and weakly by bone marrow myelocytes. CD66b is not expressed by peripheral blood monocytes or lymphocytes.

**Flow Cytometry**

Use 20ul of the suggested working dilution to label  $5 \times 10^5$  cells or 100ul whole blood.

**References**

1. Rosenkranz, A.R. *et al.* (1999) Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes. [J Am Soc Nephrol. 10: 128-35.](#)
2. Feuk-Lagerstedt, E. *et al.* (1999) Identification of CD66a and CD66b as the major galectin-3 receptor candidates in human neutrophils. [J Immunol. 163: 5592-8.](#)
3. Ottonello, L. *et al.* (1999) Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of FcγRII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins. [Blood. 93: 3505-11.](#)
4. Ottonello, L. *et al.* (2000) Monoclonal Lym-1 antibody-targeted lysis of B lymphoma cells by neutrophils. Evidence for two mechanisms of FcγRII-dependent cytolysis. [J Leukoc Biol. 68: 662-8.](#)
5. Jankowski, A. *et al.* (2002) Determinants of the phagosomal pH in neutrophils. [J Biol Chem. 277: 6059-66.](#)
6. Thickett, D.R. *et al.* (2002) A role for vascular endothelial growth factor in acute and resolving lung injury. [Am J Respir Crit Care Med. 166: 1332-7.](#)
7. Jinnouchi, A. *et al.* (2005) Local anesthetics inhibit priming of neutrophils by lipopolysaccharide for enhanced release of superoxide: suppression of cytochrome b558 expression by disparate mechanisms. [J Leukoc Biol. 78: 1356-65.](#)
8. Sekine, K. *et al.* (2006) Panning of multiple subsets of leukocytes on antibody-decorated poly(ethylene) glycol-coated glass slides. [J Immunol Methods. 313: 96-109.](#)
9. Moraes, T.J. *et al.* (2006) Abnormalities in the pulmonary innate immune system in cystic fibrosis. [Am J Respir Cell Mol Biol. 34: 364-74.](#)
10. Binet, F. and Girard, D. (2008) Novel human neutrophil agonistic properties of arsenic

- trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2. [J Leukoc Biol. 84: 1613-22.](#)
11. Nijhuis, J. *et al.* (2009) Neutrophil Activation in Morbid Obesity, Chronic Activation of Acute Inflammation [Obesity \(Silver Spring\). 17: 2014-8.](#)
  12. Pliyev, B.K. and Menshikov, M.Y. (2010) Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. [Inflammation. 33: 1-9.](#)
  13. Simard, J.C. *et al.* (2010) Induction of neutrophil degranulation by S100A9 via a MAPK-dependent mechanism. [J Leukoc Biol. 87 \(5\): 905-14.](#)
  14. Ionita, M.G. *et al.* (2010) High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. [Arterioscler Thromb Vasc Biol. 30 \(9\): 1842-8.](#)
  15. Orozco-Uribe, M. *et al.* (2015) Early Exposure of Human Neutrophils to Mycobacteria Triggers Cell Damage and Pro-Inhibitory Molecules, but not Activation [Tuberculosis Ch4](#)
  16. Whitmore, L.C. *et al.* (2016) A Common Genetic Variant in TLR1 Enhances Human Neutrophil Priming and Impacts Length of Intensive Care Stay in Pediatric Sepsis. [J Immunol. 196 \(3\): 1376-86.](#)
  17. Bastian, O.W. *et al.* (2016) Neutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury. [Clin Immunol. 164: 78-84.](#)
  18. Dyugovskaya, L. *et al.* (2016) Intermittent Hypoxia Affects the Spontaneous Differentiation *In Vitro* of Human Neutrophils into Long-Lived Giant Phagocytes. [Oxid Med Cell Longev. 2016: 9636937.](#)
  19. Bhan, I. *et al.* (2018) Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. [Gastroenterology. 155 \(6\): 2016-2018.e11.](#)
  20. Medford, A.J. *et al.* (2019) Blood-based monitoring identifies acquired and targetable driver *HER2* mutations in endocrine-resistant metastatic breast cancer. [NPJ Precis Oncol. 3: 18.](#)
  21. Ebright, R.Y. *et al.* (2020) HIF1A signaling selectively supports proliferation of breast cancer in the brain. [Nat Commun. 11 \(1\): 6311.](#)
  22. Franses, J.W. *et al.* (2020) Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. [Nat Commun. 11 \(1\): 3303.](#)
  23. Fox, D.B. *et al.* (2023) Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. [NPJ Precis Oncol. 7 \(1\): 25.](#)

---

**Storage**

Store at +4°C.

DO NOT FREEZE

This product should be stored undiluted. This product is photosensitive and should be protected from light.

Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Guarantee**

Guaranteed until date of expiry. Please see product label.

---

**Health And Safety Information**

Material Safety Datasheet documentation #10041 available at: <https://www.bio-rad-antibodies.com/SDS/MCA216F>  
10041

---

**Regulatory**

For research purposes only

---

## Related Products

### Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:FITC \(MCA928F\)](#)

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M390023:210819'

**Printed on 30 Apr 2023**

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)